Investigational drug · Phase 3
SYHA1813
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Unresectable Locally Advanced or Metastatic Solid Tumors, High Grade Meningioma, Recurrent or Progressive High Grade Meningioma.
Phase 3Last checked: Nov 19, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "SYHA1813"
First trial start
2024
Nov 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYHA1813", any sponsor or status.
Conditions studied
As listed on its trial records.
- Unresectable Locally Advanced or Metastatic Solid Tumors
- High Grade Meningioma
- Recurrent or Progressive High Grade Meningioma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYHA1813" as an intervention, largest first.
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Pivotal-lookingNot yet recruiting
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06682611 · 380 participants (planned) · Start Nov 13, 2024 · Primary completion Nov 13, 2026
Drug: SYHA1813; SG001 and 7 more · For: Unresectable Locally Advanced or Metastatic Solid Tumors
- A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade MeningiomasPivotal-lookingNot yet recruiting
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT07613450 · 136 participants (planned) · Start May 20, 2026 · Primary completion Jul 31, 2029
Drug: SYHA1813; Investigator's Choice Treatment · For: High Grade Meningioma
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06739213 · 56 participants (planned) · Start Jan 31, 2025 · Primary completion Jan 31, 2027
Drug: SYHA1813; Investigator's Choice Treatment · For: Recurrent or Progressive High Grade Meningioma
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06157918 · 19 participants · Start Dec 20, 2023 · Primary completion Jan 26, 2024
Drug: SYHA1813 oral solution (2.0g:25mg); SYHA1813 oral solution (20ml:200mg) · For: Healthy Participants
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Correction: Editorial: Advancements in meningioma management: from imaging techniques to personalized medicine approaches.
Lichtor T · Front Neurol 2026
- Editorial: Advancements in meningioma management: from imaging techniques to personalized medicine approaches.
Lichtor T · Front Neurol 2026
- SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High-Grade Gliomas: A Multicenter, Open-Label Phase I Study.
Kang Z, Li S, Wang L, et al. · Ann Clin Transl Neurol 2025
- Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma.
Shi W, Tang H, Tong L, et al. · Cancer Cell Int 2025
- A novel compound, SYHA1813, inhibits malignant meningioma growth directly by boosting p53 pathway activation and impairing DNA repair.
Lan Y, Li S, Wang J, et al. · Front Oncol 2025
- Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas.
Song PR, Wan ZP, Huang GG, et al. · Acta Pharmacol Sin 2024
Also in development for Unresectable Locally Advanced or Metastatic Solid Tumors
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- IBI3014Phase 21 trial
Innovent Biologics (Suzhou) Co. Ltd. · Unresectable Locally Advanced or Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.